IGF1 and metabolic syndrome: Nevertheless, insulin resistance abolished the effect of IGF-I on APP phosphorylation at T688, suggesting that treatment with insulin and IGF-I cannot be beneficial in AD patients with insulin resistance, metabolic syndrome, or diabetes [182].